Rasdegafusp alfa clinical trials
Also written CDX-1401 and DEC-205/NY-ESO-1 Fusion Protein CDX-1401.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses rasdegafusp alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 6
Roswell Park Cancer Institute (4) · Celldex Therapeutics (2) · Yale University (1) · Case Comprehensive Cancer Center (1)
Often tested with
Tested in the same studies.
Poly ICLC (4) · Epacadostat (1) · Resiquimod (1) · Varlilumab (1) · Atezolizumab (1)
Studies
Open first, then newest update. How each study uses rasdegafusp alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT03358719Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401How we know
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in RemissionCompletedPhase 1/2Roswell Park Cancer InstituteNCT02166905Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401How we know
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedPhase 1Roswell Park Cancer InstituteNCT01834248Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401How we know
- Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung CancerWithdrawnPhase 2Yale UniversityNCT02495636Written as CDX-1401How we know
- A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV MelanomaTerminatedPhase 1/2Celldex TherapeuticsNCT02413827Written as Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLCHow we know
- A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnPhase 1/2Case Comprehensive Cancer CenterNCT02661100Written as CDX-1401How we know
- Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsCompletedPhase 1Roswell Park Cancer InstituteNCT01522820Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401How we know
- A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1CompletedPhase 1/2Celldex TherapeuticsNCT00948961Written as CDX-1401 in combination with Resiquimod and/or Poly-ICLCHow we know
Given beside what is tested · 2 — rasdegafusp alfa is usual care or a partner of the new treatment
- Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedPhase 1/2National Cancer Institute (NCI)NCT03206047Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401How we know
- A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT02129075Written as DEC-205/NY-ESO-1 Fusion Protein CDX-1401How we know
Codes
What other systems call rasdegafusp alfa · ClinicalTrials.gg INT017942
- UNII (FDA) SU9AMV39DBRASDEGAFUSP ALFAOne source FDA
- NCI Thesaurus C170362Rasdegafusp AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | SU9AMV39DB | RASDEGAFUSP ALFA | One source FDA |
| NCI Thesaurus | C170362 | Rasdegafusp Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.